Cytori Therapeutics Receives Frost & Sullivan 2016 Technology Innovation Award
OREANDA-NEWS. Cytori Therapeutics, Inc. today announced that it has received the Frost & Sullivan 2016 Technology Innovation Award in recognition of advancements made in the field of regenerative medicine for over a decade. Frost & Sullivan’s industry research and benchmarking analysis report that Cytori’s pioneering technology platform has become the leading technology to enable the research and practice of cellular therapies that harness the potential of stem and regenerative cells from adipose tissue.
Frost & Sullivan Industry Analyst Cecilia Van Cauwenberghe commented, “Cytori is devoted to the development of cellular therapeutics as its Cell Therapy™ platform exploits the unique attributes of adipose derived stem cells for repair and healing. With a strong intellectual property portfolio of 89 patents, a broad spectrum of pre-clinical and clinical trials, and an extensive network of distribution and commercialization partners, we believe Cytori has become a global leader in the cell therapeutics market. We are pleased to confer this technology innovation award on Cytori Therapeutics.”
“Our team is honored to receive the 2016 technology innovation award,” said Dr. Marc H. Hedrick, President and Chief Executive Officer of Cytori. “Frost & Sullivan is a leader in evaluating markets and forecasting business opportunity and this award is a clear recognition of the hard work and dedication of many - both our employees and the doctors and patients with whom we have worked over the years.”
For more information about Cytori Therapeutics, the Frost & Sullivan 2016 Technology Innovation Award, and the Frost & Sullivan Report Cell Therapeutics - North America Technology Innovation Award on Cytori Therapeutics.
About CytoriCytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products.
Комментарии